{"entity":{"id":"thomas-powles","kind":"person","name":"Thomas Powles","aka":[],"tldr":"Led EV-302, NIAGARA and IMvigor011, the trials that transformed bladder cancer from chemotherapy-only to ADC, immunotherapy and ctDNA-guided care.","summary":"Thomas Powles was principal investigator of EV-302, which showed enfortumab vedotin plus pembrolizumab nearly doubles survival versus chemotherapy in first-line advanced urothelial cancer, of NIAGARA (perioperative durvalumab), of JAVELIN Bladder 100 (avelumab maintenance) and of IMvigor011, the first trial to show ctDNA can select who benefits from adjuvant immunotherapy. He also led KEYNOTE-426 and CLEAR analyses in kidney cancer. He is among the most cited investigators in GU oncology.","asOf":"2026-09-10","links":[{"label":"Barts Cancer Institute","url":"https://www.bartscancer.london/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Powles%20T%5BAuthor%5D%20urothelial"}],"tags":["urothelial","adc","ctdna","trialist"],"related":[],"cancers":["urothelial","rcc"],"sections":[],"technologies":["adc","checkpoint-inhibitor","mrd-testing"],"targets":["nectin4","pd1","pdl1"],"drugs":["enfortumab-vedotin","pembrolizumab","durvalumab","atezolizumab","signatera"],"companies":[],"institutions":["barts-cancer-institute"],"pathways":[],"terms":[],"trials":["ev-302","niagara","javelin-bladder-100","imvigor011","keynote-426"],"people":[],"bottlenecks":[],"keyPapers":["paper-ev-302-nejm-2024","paper-niagara-nejm-2024","paper-imvigor011-nejm-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Genitourinary Oncology and Director, Barts Cancer Centre, Queen Mary University of London","institutionId":"barts-cancer-institute","specialisms":["Urothelial cancer","Renal cell carcinoma","Antibody-drug conjugates","Immunotherapy","Circulating tumour DNA"],"profiles":[{"label":"Barts Cancer Institute","url":"https://www.bartscancer.london/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Powles%20T%5BAuthor%5D%20urothelial"}],"papers":[{"title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer (EV-302)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2312117"},{"title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer (NIAGARA)","journal":"NEJM","year":2024,"doi":"10.1056/NEJMoa2408154"},{"title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma (JAVELIN Bladder 100)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2002788"},{"title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","journal":"Nature","year":2021,"doi":"10.1038/s41586-021-03642-9"},{"title":"IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery","journal":"New England Journal of Medicine","year":2025,"url":"https://clinicaltrials.gov/study/NCT04660344"}],"orcid":"0000-0001-7760-4724"},"route":"/people/thomas-powles/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"target":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/"}],"institution":[{"id":"barts-cancer-institute","kind":"institution","name":"Barts Cancer Institute / Barts Health NHS Trust","route":"/institutions/barts-cancer-institute/"}],"trial":[{"id":"ev-302","kind":"trial","name":"EV-302 / KEYNOTE-A39","route":"/trials/ev-302/"},{"id":"imvigor011","kind":"trial","name":"IMvigor011","route":"/trials/imvigor011/"},{"id":"javelin-bladder-100","kind":"trial","name":"JAVELIN Bladder 100","route":"/trials/javelin-bladder-100/"},{"id":"keynote-426","kind":"trial","name":"KEYNOTE-426","route":"/trials/keynote-426/"},{"id":"niagara","kind":"trial","name":"NIAGARA","route":"/trials/niagara/"}],"paper":[{"id":"paper-ev-302-nejm-2024","kind":"paper","name":"EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer","route":"/key-papers/paper-ev-302-nejm-2024/"},{"id":"paper-imvigor011-nejm-2025","kind":"paper","name":"IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery","route":"/key-papers/paper-imvigor011-nejm-2025/"},{"id":"paper-niagara-nejm-2024","kind":"paper","name":"NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer","route":"/key-papers/paper-niagara-nejm-2024/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"}]}}